VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
VERAXA Biotech presents first in vivo proof-of-concept for BiTAC®-ADC: tumor-selective activation with potent anti-tumor efficacy and improved safety.
Covered in this story
Call it yourself
No calls on $ADC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Agree Realty →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.